The Drop of Allergen Immunotherapy for Respiratory Allergy in Italy: An Assessment of Sales
Summary Allergen immunotherapy sales in Italy experienced a sharp decline between 2008 and 2016, followed by a more gradual decrease through 2023. Differences in reimbursement, along with structural, educational, and regulatory factors, likely contributed to the decline, and warrant further research.
Authors
- Francesco Pegoraro (ORCID: https://orcid.org/0000-0002-4954-5744)
- Cristiano Caruso (ORCID: https://orcid.org/0000-0001-7631-029X)
- Mattia Giovannini (ORCID: https://orcid.org/0000-0001-9568-6882)
- Domenico Gargano (ORCID: https://orcid.org/0000-0003-4677-3730)
- Simona Barbaglia
- Giorgio Walter Canonica (ORCID: https://orcid.org/0000-0001-8467-2557)
- Antonio Bognanni (ORCID: https://orcid.org/0000-0003-0128-903X)
- Enrico Marco Heffler (ORCID: https://orcid.org/0000-0002-0492-5663)
- Giovanni Paoletti (ORCID: https://orcid.org/0000-0003-3953-9225)
- Luisa Brussino
Institutions
- Humanitas University (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- Meyer Children's Hospital (IT)
- ANT Foundation Italy Onlus (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- University of the Sacred Heart (JP)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Florence (IT)
- University of Turin (IT)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1111/cea.70183
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Allergy Therapeutics